A spontaneous report is an unsolicited communication about one or more suspected adverse drug reactions in an individual, submitted by a healthcare professional or a consumer to a company, an authority, or another organization. It does not originate from a study or an organized data collection system. In the pharmacovigilance process, the term therefore indicates the origin of a case report.
What Constitutes a Spontaneous Report
ICH E2D describes a spontaneous report as a communication about suspected adverse drug reactions in a patient who has received one or more medicinal products. The unsolicited nature of the information is crucial. The transmission route can be a reporting form, a phone call, an email, or another form of contact; the report does not have to originate from a medical professional.
Consumer reports are also treated as spontaneous, even if medical confirmation is added later. For internet cases, it must be checked whether the patient and the reporter are identifiable as real persons. The fact that information originates from the press, other media, or an online source does not automatically render it unusable, but it changes the requirements for traceability and completeness.
For an authorized medicinal product, a spontaneously reported adverse reaction generally implies a suspected causal relationship. Therefore, it is not decisive whether the reporting person has explicitly assessed the relationship. The quality and completeness of the case then determine whether the minimum criteria are met and what processing follows in the safety process.
Stimulated Reports and Case Follow-up
A report remains spontaneous if it was prompted by an external event but did not arise from an organized data collection system. ICH E2D mentions, for example, information in a Dear Healthcare Professional letter, press publications, or questions from company employees to healthcare professionals. Such stimulated reports must not be reclassified as solicited reports solely because of the trigger.
After receipt, the marketing authorization holder may obtain supplementary information, for example, on the medicinal product name, temporal course, concomitant diseases, dose, outcome, or identity of the reporter. This follow-up does not change the original type of report. Its purpose is to transform an initially brief communication into a medically assessable individual case safety report and, if necessary, to supplement missing minimum information.
Spontaneous cases are not only included in individual case processing. GVP Module VII names spontaneous individual case reports from healthcare professionals, consumers, scientific literature, and competent authorities as sources for PSUR tables. A single unusual course or an accumulation of comparable cases can also become relevant for signal detection.
Distinction: Counterpart to Solicited Reports
The spontaneous report is the counterpart to the solicited report. A solicited report arises within an organized system, such as a registry, a patient support program, a survey, or a clinical study. There, data are collected according to a predefined procedure; the spontaneous report, however, begins with unsolicited information.
This distinction has a concrete consequence for processing. For organized sources, a different ICH E2D logic applies: the case is treated as a study report, and its possible drug-relatedness must be explicitly medically assessed. In the case of a spontaneous report, the presumption of a connection is attributed to the report by its reporting type.
The existing glossary entry ‘Adverse Event Report’ describes the general process by which information about events is collected and disseminated. ‘Spontaneous Report’ more narrowly defines the non-organized context from which safety information originates. It is therefore not a designation for every report, nor is it a synonym for the electronic individual case safety report.
Relevance for clinical trials
In clinical studies, it must be clear whether information was received through planned study data collection or outside this framework. For study sites, events recorded in the protocol do not automatically fall into the spontaneous case category; at the same time, unsolicited communications received after authorization regarding an investigational medicinal product can reveal new risks. Safety officers must separately document the input channel, source documents, medical assessment, and necessary follow-up inquiries.
Full-service CROs like Mediconomics support spontaneous reports by establishing verifiable reception channels, triaging incoming information, targeted follow-up with reporters, and coding medical data. Pharmacovigilance teams can also check whether a case meets the minimum criteria, if a safety report needs to be created, and what information must be relayed to study management or regulatory affairs.
Frequently Asked Questions (FAQ)
Is a reaction from a Dear Healthcare Professional letter a solicited report?
No. ICH E2D classifies reports prompted by such a communication as stimulated reports; these are to be treated as spontaneous reports, provided no organized data collection system exists.
Can a consumer submit a spontaneous report?
Yes. Unsolicited consumer reports are explicitly considered spontaneous reports, even if medical confirmation is later provided or required by an authority.
Does a spontaneous report become a solicited report after a follow-up inquiry?
No. Obtaining missing clinical information is follow-up to an already received case. It does not establish a new organized data collection system and therefore does not change the original reporting type.
Regulatory References
- ICH E2D, Post-Approval Safety Data Management – defines spontaneous and stimulated reports.
- GVP Module VI, Management and Reporting of Adverse Reaction Reports – addresses the processing of individual case information.
- GVP Module VII, Periodic Safety Update Report – names spontaneous individual case reports as an evaluation source.
- Directive 2001/83/EC, Title IX – forms the EU framework for pharmacovigilance.